Bolt Biotherapeutics (NASDAQ:BOLT) — Market Cap & Net Worth
Market Cap & Net Worth: Bolt Biotherapeutics (BOLT)
Bolt Biotherapeutics (NASDAQ:BOLT) has a market capitalization of $7.93 Million ($7.93 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27411 globally and #5429 in its home market, demonstrating a 6.08% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bolt Biotherapeutics's stock price $5.06 by its total outstanding shares 1919441 (1.92 Million). Analyse BOLT cash flow metrics to see how efficiently the company converts income to cash.
Bolt Biotherapeutics Market Cap History: 2021 to 2026
Bolt Biotherapeutics's market capitalization history from 2021 to 2026. Data shows change from $9.41 Million to $9.71 Million (-29.75% CAGR).
Index Memberships
Bolt Biotherapeutics is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #800 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2593 of 3165 |
Weight: Bolt Biotherapeutics's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Bolt Biotherapeutics Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bolt Biotherapeutics's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.13x
Bolt Biotherapeutics's market cap is 0.13 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $9.41 Million | $1.26 Million | -$98.59 Million | 7.46x | N/A |
| 2022 | $2.50 Million | $5.73 Million | -$88.10 Million | 0.44x | N/A |
| 2023 | $2.15 Million | $7.88 Million | -$69.20 Million | 0.27x | N/A |
| 2024 | $1.03 Million | $7.69 Million | -$63.12 Million | 0.13x | N/A |
Competitor Companies of BOLT by Market Capitalization
Companies near Bolt Biotherapeutics in the global market cap rankings as of May 4, 2026.
Key companies related to Bolt Biotherapeutics by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Bolt Biotherapeutics Historical Marketcap From 2021 to 2026
Between 2021 and today, Bolt Biotherapeutics's market cap moved from $9.41 Million to $ 9.71 Million, with a yearly change of -29.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $9.71 Million | -7.46% |
| 2025 | $10.50 Million | +921.87% |
| 2024 | $1.03 Million | -52.22% |
| 2023 | $2.15 Million | -13.85% |
| 2022 | $2.50 Million | -73.47% |
| 2021 | $9.41 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Bolt Biotherapeutics was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.93 Million USD |
| MoneyControl | $7.93 Million USD |
| MarketWatch | $7.93 Million USD |
| marketcap.company | $7.93 Million USD |
| Reuters | $7.93 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform th… Read more